Alpha Cognition Secures $35 Million in Oversubscribed Public Offering to Accelerate Neurodegenerative Disease Treatments

Alpha Cognition Inc. (NASDAQ: ACOG), a commercial-stage biopharmaceutical company focused on neurodegenerative disease treatments, has announced the pricing of its oversubscribed underwritten public offering. The company will issue 5.6 million common shares at $6.25 per share, generating approximately $35 million in gross proceeds before expenses. This significant capital infusion represents a strong vote of confidence from the investment community in Alpha Cognition's therapeutic pipeline and commercial strategy.

The net proceeds from this offering are earmarked to accelerate the commercialization of ZUNVEYL (Benzgalantamine), the company's patented drug approved as a new generation acetylcholinesterase inhibitor for Alzheimer's disease treatment. Specific allocation includes sales expansion, marketing initiatives, payer coverage development, and reimbursement infrastructure. According to CEO Michael McFadden, this funding will help maximize near-term adoption while establishing the foundation for long-term growth. The oversubscribed nature of the offering indicates robust investor interest in neurodegenerative disease treatments, particularly those addressing conditions with limited therapeutic options.

ZUNVEYL represents a significant advancement in Alzheimer's treatment due to its differentiated mechanism of action and expected minimal gastrointestinal side effects. The drug's active metabolite binds neuronal nicotinic receptors, specifically the alpha-7 subtype, which is known to have positive effects on cognition. This differentiation from existing treatments like donepezil and rivastigmine could potentially offer improved patient outcomes and tolerability. The successful funding round enables Alpha Cognition to expand access to this innovative therapy more rapidly than previously planned.

Beyond ZUNVEYL for Alzheimer's disease, Alpha Cognition is developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia and as an intranasal formulation for Cognitive Impairment with mild Traumatic Brain Injury (mTBI). These development programs address significant unmet medical needs, as there are currently no approved treatment options for Cognitive Impairment with mTBI. The company's broader pipeline targeting multiple neurodegenerative conditions positions it as an emerging leader in this challenging therapeutic area.

Titan Partners Group, a division of American Capital Partners, served as sole bookrunner for the offering and was granted a 30-day option to purchase up to an additional 840,000 shares to cover over-allotments. This additional capacity provides further financial flexibility and reflects the strong market reception to Alpha Cognition's offering. The successful capital raise comes at a critical time for neurodegenerative disease research, with growing recognition of the substantial medical and economic burden these conditions place on healthcare systems worldwide.

The implications of this funding extend beyond Alpha Cognition's immediate commercial objectives. For patients and families affected by Alzheimer's disease and other neurodegenerative conditions, accelerated commercialization of ZUNVEYL could mean earlier access to potentially improved treatment options. For the broader biopharmaceutical industry, this successful offering demonstrates continued investor confidence in neurodegenerative disease therapeutics despite the historical challenges in this development area. The funding also supports ongoing research into combination therapies and alternative formulations that could expand treatment options across the neurodegenerative disease spectrum.

For more information about Alpha Cognition's development programs, visit https://www.alphacognition.com/. Additional details about the public offering and corporate developments can be found through the company's regulatory filings and investor communications. The progress in neurodegenerative disease treatments represents an important step forward in addressing conditions that affect millions of patients worldwide and their families.